Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
Trimodality therapy is an effective potential alternative to radical cystectomy for recurrent high-grade T1 urothelial cancer of the bladder. At 3 years, 88% of the patients remained free of cystectomy.
Authors
- Joseph P. Rodgers
- Douglas M. Dahl (ORCID: https://orcid.org/0000-0002-9084-9627)
- William U. Shipley (ORCID: https://orcid.org/0009-0008-0887-8391)
- Felix Yi-Chung Feng (ORCID: https://orcid.org/0000-0002-0963-7687)
- A. Jani (ORCID: https://orcid.org/0000-0002-1687-6221)
- M. Dror Michaelson (ORCID: https://orcid.org/0000-0001-9249-6338)
- Theodore Karrison (ORCID: https://orcid.org/0009-0009-8641-5111)
- Jeff M. Michalski (ORCID: https://orcid.org/0000-0003-0563-3766)
- Howard M. Sandler (ORCID: https://orcid.org/0000-0002-8193-5769)
- Chin‐Lee Wu (ORCID: https://orcid.org/0000-0002-0444-0068)
- Jason A. Efstathiou (ORCID: https://orcid.org/0000-0003-0996-0350)
- Daniel Y. Song (ORCID: https://orcid.org/0000-0002-3495-8677)
- Deborah E. Citrin (ORCID: https://orcid.org/0000-0002-4391-2734)
- Richard Hudes (ORCID: https://orcid.org/0000-0001-5166-7436)
- Alan C. Hartford (ORCID: https://orcid.org/0000-0003-2273-7882)
- Fabio Cury (ORCID: https://orcid.org/0000-0003-1293-0822)
- William Parker
Institutions
- Cedars-Sinai Medical Center (US)
- Dartmouth–Hitchcock Medical Center (US)
- Saint Agnes Hospital (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Emory University (US)
- Washington University in St. Louis (US)
- Thomas Jefferson University Hospital (US)
- McGill University Health Centre (CA)
- Massachusetts General Hospital (US)
- Sidney Kimmel Cancer Center (US)
- University of California San Francisco Medical Center (US)
- National Institutes of Health Clinical Center (US)
- NRG Oncology (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Winship Cancer Institute
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1200/jco.23.02510
- Citations
- 20
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 11.46
Funders
- NRG Oncology
- National Cancer Institute